FDA approves TAUKLARIFY, new molecular entity from Cerveau Lantheus
The intravenous imaging agent received standard approval under NDA220496, with submission status recorded as of August 13, 2026.
Drugs@FDA
Latest
3 stories
Thursday, August 13
Thursday, August 6
Lantheus posts Q2 2026 results, pulls guidance amid pending Curium merger
Lantheus reported second-quarter revenue of $388.2 million and said it is suspending its 2026 outlook as it awaits closing of its acquisition by Curium US Holdings.
SEC filing
Monday, August 3
Lantheus merger with Curium subsidiary confirmed at up to $114.50 per share
A Curium merger unit will merge into Lantheus, which survives as Curium's subsidiary, with holders getting $102.50 cash plus CVRs worth up to $12.00.
SEC filing